Finance

Lists
AMGN:NASDAQ
Amgen Inc
421,51 $
-0,50%
(-2,13) 1D
421,00 $
-0,12% (-0,51)
After hours
Closed: 30 սեպ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMGN...
Open
424,01 $
High
426,59 $
Low
420,63 $
Mkt. cap
227,88 մլրդ
Avg. vol.
2,89 մլն
Volume
2,91 մլն
Dividend
2,39%
Quarterly dividend
2,52 $
Ex-dividend date
21 օգս, 2026 թ.
P/E ratio
26,18
52-wk high
447,01 $
52-wk low
283,00 $
EPS
16,10 $
Beta
0,43
Shares outstanding
540,63 մլն
No. of employees
32 հզր
Open
424,01 $
High
426,59 $
Low
420,63 $
Mkt. cap
227,88 մլրդ
Avg. vol.
2,89 մլն
Volume
2,91 մլն
Dividend
2,39%
Quarterly dividend
2,52 $
Ex-dividend date
21 օգս, 2026 թ.
P/E ratio
26,18
52-wk high
447,01 $
52-wk low
283,00 $
EPS
16,10 $
Beta
0,43
Shares outstanding
540,63 մլն
No. of employees
32 հզր
News stories
From web sources and news partners
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31,5 հզր
Founded08 ապր, 1980 թ.
HeadquartersԹաուզենդ Օուքս, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websiteamgen.com
Analyst ratings
Based on 27 analysts giving stock ratings to AMGN in the past 3 months
Buy
Buy
9
Hold
16
Sell
2
12-month forecast
Based on 27 Wall Street analysts offering 12 month price targets for AMGN in the last 3 months.
Highest
Current 421,51 $
500,00 $ (+18,62%)
Average
401,39 $ (-4,77%)
Lowest
230,00 $ (-45,43%)
Analyst
Recommendation
Action
Price target
Projected
Date
Louise Chen
Scotiabank
Buy
Maintained
500,00 $
+18,6%
09/29/2026
Christopher Raymond
Raymond James
Hold
Maintained
-
-
09/24/2026
Unknown Analyst
Leerink Partners
Hold
Maintained
-
-
09/23/2026
Unknown Analyst
Jefferies
Hold
Maintained
410,00 $
-2,7%
09/23/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
450,00 $
+6,8%
09/22/2026
David Amsellem
Piper Sandler
Buy
Reiterated
457,00 $
+8,4%
09/23/2026
Gregory Renza
Truist Financial
Hold
Maintained
-
-
09/23/2026
Gary Nachman
Canaccord Genuity
Hold
Maintained
384,00 $
-8,9%
09/23/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
362,00 $
-14,1%
09/22/2026
Tazeen Ahmad
Bank of America Securities
Sell
Maintained
317,00 $
-24,8%
09/22/2026
Yaron Werber
TD Cowen
Buy
Reiterated
452,00 $
+7,2%
09/22/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/22/2026
Geoff Meacham
Citi
Hold
Maintained
405,00 $
-3,9%
09/23/2026
Mohit Bansal
Wells Fargo
Hold
Reiterated
435,00 $
+3,2%
09/22/2026
Evan Seigerman
BMO Capital
Hold
Maintained
450,00 $
+6,8%
09/16/2026
Michael Yee
UBS
Buy
Reiterated
430,00 $
+2%
09/17/2026
Emily Field
Barclays
Hold
Maintained
380,00 $
-9,8%
09/17/2026
Morten Herholdt
HSBC
Hold
Downgraded
425,00 $
+0,8%
09/09/2026
Carter Gould
Cantor Fitzgerald
Hold
Maintained
400,00 $
-5,1%
09/05/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
460,00 $
+9,1%
08/18/2026
Salim Syed
Mizuho Securities
Hold
Maintained
352,00 $
-16,5%
08/17/2026
Chris Schott
J.P. Morgan
Hold
Maintained
350,00 $
-17%
08/06/2026
Vamil Divan
Guggenheim
Hold
Maintained
388,00 $
-7,9%
08/07/2026
Courtney Breen
Bernstein
Hold
Maintained
345,00 $
-18,2%
08/05/2026
Jay Olson
Oppenheimer
Buy
Maintained
450,00 $
+6,8%
08/05/2026
Luca Issi
RBC Capital
Buy
Maintained
400,00 $
-5,1%
08/05/2026
Brian Skorney
Robert W. Baird
Sell
Maintained
230,00 $
-45,4%
08/05/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Upgraded
375,00 $
-11%
05/07/2026
Hans Engel
Erste Group
Hold
Downgraded
-
-
05/05/2026
Unknown Analyst
Raymond James
Hold
Reiterated
-
-
05/01/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
05/01/2026
Unknown Analyst
J.P. Morgan
Hold
Initiated
300,00 $
-28,8%
05/01/2026
Unknown Analyst
Canaccord Genuity
Hold
Initiated
366,00 $
-13,2%
04/21/2026
Akash Tewari
Jefferies
Hold
Initiated
350,00 $
-17%
03/10/2026
Unknown Analyst
Argus Research
Buy
Maintained
400,00 $
-5,1%
02/06/2026
Last report
04 օգս, 2026 թ.
Fiscal period
Q2 2026
EPS / Est. (USD)
6,29 $ / 5,62 $
+11,97%beat
Revenue / Est. (USD)
10,05 մլրդ / 9,42 մլրդ
+6,73%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
9,56 մլրդ
9,87 մլրդ
8,62 մլրդ
10,05 մլրդ
Cost of goods sold
2,74 մլրդ
2,68 մլրդ
2,50 մլրդ
2,75 մլրդ
Cost of revenue
2,74 մլրդ
2,68 մլրդ
2,50 մլրդ
2,75 մլրդ
Research and development expenses
1,90 մլրդ
2,14 մլրդ
1,72 մլրդ
1,87 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,72 մլրդ
1,95 մլրդ
1,60 մլրդ
1,74 մլրդ
Operating expense
3,55 մլրդ
4,18 մլրդ
3,21 մլրդ
3,73 մլրդ
Total operating expenses
6,29 մլրդ
6,85 մլրդ
5,70 մլրդ
6,48 մլրդ
Operating income
3,26 մլրդ
3,01 մլրդ
2,91 մլրդ
3,57 մլրդ
Other non operating income
181,00 մլն
143,00 մլն
192,00 մլն
145,00 մլն
EBT including unusual items
3,92 մլրդ
1,51 մլրդ
2,08 մլրդ
2,77 մլրդ
EBT excluding unusual items
2,72 մլրդ
2,51 մլրդ
2,37 մլրդ
3,06 մլրդ
Income tax expense
705,00 մլն
181,00 մլն
265,00 մլն
393,00 մլն
Effective tax rate
17,98%
11,96%
12,72%
14,20%
Other operating expenses
-71,00 մլն
82,00 մլն
-113,00 մլն
116,00 մլն
Net income
3,22 մլրդ
1,33 մլրդ
1,82 մլրդ
2,38 մլրդ
Net profit margin
33,65%
13,51%
21,11%
23,62%
Earnings per share
5,64
5,29
5,15
6,29
Interest and investment income
-
408,00 մլն
-
-
Interest expense
-685,00 մլն
-1,06 մլրդ
-657,00 մլն
-673,00 մլն
Net interest expenses
-685,00 մլն
-653,00 մլն
-657,00 մլն
-673,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
4,57 մլրդ
4,02 մլրդ
4,03 մլրդ
4,69 մլրդ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps